An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients

AIDS

Volumn 15, Issue 18, 2001, Pages 2397-2406

  Fauvel, J ^a   Bonnet, E ^a   Ruidavets, J B ^a   Ferrieres J ^a   Toffoletti, A ^a   Massip, P ^a   Chap, H ^a   Perret, B ^a  

^a CHU PURPAN   (France)

Author keywords

Apolipoprotein C III; Dyslipidaemia; Lipoparticle; Polymorphism; Protease inhibitor

Indexed keywords

APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ENDONUCLEASE; HIGH DENSITY LIPOPROTEIN; PROTEINASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ALLELE; ARTICLE; DNA POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ALLELES; APOLIPOPROTEIN C-III; APOLIPOPROTEINS C; APOLIPOPROTEINS E; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HIV-1; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS, HDL; MALE; POLYMORPHISM, GENETIC; PROTEASE INHIBITORS; TRIGLYCERIDES; VARIATION (GENETICS);

EID: 0035824763     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200112070-00007     Document Type: Article

References (46)

1. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
2. Atherogenic dyslipemia in HIV-infected individuals with protease inhibitors
3. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
4. Indinavir-associated lipodystrophy
5. Visceral abdominal-fat accumulation associated with use of indinavir
6. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
7. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
8. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro
9. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors
10. HIV protease inhibitors stimulate hepatic triglyceride synthesis
11. Apolipoprotein C-III and E-containing lipopartides are markedly increased in HIV-infected patients treated with protease inhibitors: Association with the development of lipodystrophy
12. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat
13. Effects of polymorphisms in apolipoproteins E, A IV, and H on quantitative traits related to risk of cardiovascular disease
14. Variability gene effects of DNA polymorphisms at the apo B, apo AI/C-IIII and apo E loci on serum lipids: The Cardiovascular Risk in Young Finns Study
15. Increased risk for endogenous hypertriglyceridemia is associated with an apolipoprotein C3 haplotype specified by the Sstl polymorphism
16. A variation in the apolipoprotein C-III gene is associated with an increased number of circulating VLDL and IDL particles in familial combined hyperlipidemia
17. An apolipoprotein C-III haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms
18. Common genetic variation in the promoter of the human apo C-III gene abolishes regulation by insulin and may contribute to hypertriglyceridemia
19. Hypertriglyceridemia and the apolipoprotein C-III gene locus: Lack of association with the variant insulin response element in Italian school children
20. Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia
21. Association of plasma lipids and apolipoproteins with the insulin response element in the apo C-III promoter region in familial combined hyperlipidemia
22. Impact of the 1993 revision of the AIDS case definition on the prevalence of AIDS in a clinical setting
23. Using RT-PCR and bDNA assays to measure non-clade B HIV-1 subtype RNA
24. Apolipoproteins C-III and E in apoB- and non-apoB containing lipoproteins in two populations at contrasting risk for myocardial infarction: The ECTIM study
25. A simple salting out procedure for extracting DNA from human nucleated cells
26. Restriction isotyping of human apolipoprotein E by gene amplification and cleavege by Hhal
27. Trends in acute myocardial infarction prognosis and treatment in SouthwesternFrance between 1985 and 1990 (the MONICA Project-Toulouse)
28. Apo E genotype and protease-inhibitor-associated hyperlipidemia
29. Variation at the lipoprotein lipase and apolipoprotein AI-C-III gene loci are associated with fasting lipids and lipoprotein traits in a population sample from Iceland: Interaction between genotype, gender and smoking status
30. Common genetic variations in the apo C3 promoter associated with variation in plasma lipoproteins
31. Gender related association between genetic variations of apo C-III gene and lipid and lipoprotein variables in northern France
32. Apo C-III gene variants modulate postprandial response to both glucose and fat tolerance tests
33. The Sstl polymorphism of the apolipoprotein C-III gene determines the insulin response to an oral-glucose-tolerance test after consumption of a diet rich in saturated fats
34. Human apolipoprotein C-III gene expression is regulated by positive and negative cis-acting elements and tissue-specific protein factors
35. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation
36. A decade of molecular biology of retinoic acid receptors
37. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
38. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) C-III transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo C-III and reduced apo E on the partides
39. Modulation of lipoproteinlipase activity by apolipoproteins Effect of apolipoprotein C-III
40. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, C-III, and E
41. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein
42. Very low density lipoprotein. Removal of apolipoproteins C-II and C-III-1 during lipolysis in vitro
43. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment
44. In vitro production of human plasma low density-like particles. A model for very low density lipoprotein catabolism
45. Lipoprotein lipase gene polymorphism, cholesterol subfractions and myocardial infarction in large samples of the general population
46. The T allele of the hepatic lipase promoter variant C-480T is associated with increased fasting lipids and HDL and increased preprandial and postprandial Lp C-III: B: European Atherosclerosis Research Study (EARS) II